<DOC>
	<DOCNO>NCT00746590</DOCNO>
	<brief_summary>This open-label study design evaluate anti-tumour activity safety Prolarix subject advance hepatocellular carcinoma . Prolarix chemotherapy comprise tretazicar prodrug caricotamide co-substrate endogenous enzyme , NQO2 .</brief_summary>
	<brief_title>Study Anti-tumour Effects Safety Prolarix™ Hepatocellular Carcinoma</brief_title>
	<detailed_description>The primary objective study evaluate anti-tumour effect treatment Prolarix subject advanced HCC ( Child-Pugh A B ) . All subject receive IV infusion Prolarix every 21 day disease progression observe . Subjects CT scan tumour measurement start treatment Prolarix every 6 week disease progression . Subjects undergo evaluation safety ( adverse event , vital sign , clinical laboratory measurement , weight , ECG ) every 21 day disease progression .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Tretazicar</mesh_term>
	<criteria>Subject must least 18 year age . Subject must histologic cytologic diagnosis HCC consider unsuitable resection potentially curative option ( eg , liver transplant , curative radiofrequency ablation ) . Subject must measurable lesion RECIST CT scan least one site receive radiation local therapy [ eg , transcatheter arterial chemoembolisation ( TACE ) , radiofrequency ablation , local injection ] . ( Note : Subjects receive local therapy allow participate , provide target lesion subject local therapy . Subjects receive TACE must target lesion outside vascular territory subject chemoembolisation . ) Subject Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 . Subject active malignancy within past three year [ non melanomatous skin cancer carcinoma situ ( CIS ) breast , bladder , uterine cervix . Subjects Ta ( noninvasive papillary carcinoma ) Tis ( sessile carcinoma situ ) bladder cancer allow ] . Subject minimum life expectancy least three month determine investigator . Subject adequate bone marrow function ( ie , haemoglobin ≥9 g/dL , granulocytes ≥1500/mm3 , platelets ≥75,000/mm3 ) . Prothrombin time ( PT ) international normalise ratio ( INR ) ≤2.3 PT ≤6 second control . ( Note : Subjects therapeutically anticoagulated agent warfarin heparin allow participate provide INR 2.0 3.0 . Subject adequate renal function ( ie , serum creatinine normal calculated creatinine clearance ≥60 mL/min ) . Subject adequate hepatic function ( ie , bilirubin ≤2x upper limit normal ( ULN ) ; AST ALT , alkaline phosphatase ≤5xULN ) . ( Also see exclusion ChildPugh class C ) . Male subject females childbearing potential must agree use adequate method contraception time initiation treatment study participation 3 month release study . Subject able give inform consent . Any prior current systemic pharmacotherapy HCC ( cytotoxic , target biologic ) . ( Note : TACE consider systemic pharmacotherapy purpose study ) . Subject absolute contraindication receive CT contrast medium . ( Note : Subjects history minor contrast reaction may premedicated prior contrast administration accordance local institutional practice ) . Subject ChildPugh Class C hepatic impairment . Subject receive investigational drug within 30 day enrolment study . Females childbearing potential unless use adequate contraception . Pregnant lactating female . Major variceal bleed last 30 day . Subjects know history human immunodeficiency virus ( HIV ) infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>liver cancer</keyword>
	<keyword>Prolarix</keyword>
	<keyword>tretazicar</keyword>
	<keyword>caricotamide</keyword>
	<keyword>Phase 2</keyword>
	<keyword>tumor</keyword>
	<keyword>chemotherapy</keyword>
</DOC>